Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

17.39
-0.5200-2.90%
Post-market: 17.35-0.0400-0.23%19:59 EDT
Volume:3.51M
Turnover:61.66M
Market Cap:1.70B
PE:-29.03
High:18.21
Open:17.97
Low:17.23
Close:17.91
52wk High:138.81
52wk Low:10.42
Shares:97.71M
Float Shares:88.22M
Volume Ratio:0.60
T/O Rate:3.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5989
EPS(LYR):2.47
ROE:-4.76%
ROA:-0.02%
PB:1.25
PE(LYR):7.03

Loading ...

Roche Holding Ag: Boy Passed Away in Brazil Was Treated With Elevidys and Was Not a Participant in a Clinical Trial

THOMSON REUTERS
·
Jul 26

Roche Holding Ag -Reporting Physician Has Assessed Death as Unrelated to Treatment With Elevidys

THOMSON REUTERS
·
Jul 26

FDA: Investigating Death of 8-Year-Old Boy Who Received Elevidys

THOMSON REUTERS
·
Jul 26

Sarepta Shares Down 10% After Its Gene Therapy Fails to Secure EU Backing

THOMSON REUTERS
·
Jul 25

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Jul 25

Sarepta Therapeutics Inc. Acknowledges CHMP Negative Opinion on ELEVIDYS, Continues Regulatory Review with EMA for Duchenne Therapy in EU

Reuters
·
Jul 25

Sarepta Therapeutics Inc - Roche to Continue Dialogue With Ema for Elevidys in EU

THOMSON REUTERS
·
Jul 25

Sarepta Therapeutics Inc - Actively Working With FDA to Address Recent Safety Questions

THOMSON REUTERS
·
Jul 25

Sarepta Therapeutics Acknowledges Chmp Negative Opinion for Elevidys in the European Union

THOMSON REUTERS
·
Jul 25

Sarepta Shares Fall After Elevidys Fails to Receive European Approval

MT Newswires Live
·
Jul 25

Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $6 From $9, Maintains Sell Rating

MT Newswires Live
·
Jul 25

Top Premarket Decliners

MT Newswires Live
·
Jul 25

Stock Track | Sarepta Therapeutics Plunges 13% Pre-Market on EU Rejection and Brazil Suspension of Gene Therapy

Stock Track
·
Jul 25

Sarepta Therapeutics Shares Down 12.7% Premarket After EU Regulator Says It Did Not Recommend Approval of Co's Muscle Disorder Therapy

THOMSON REUTERS
·
Jul 25

Sarepta Shares Fall as Brazil Temporarily Suspends Gene Therapy Drug

MT Newswires Live
·
Jul 25

Sarepta Therapeutics Shares Fall as European Medicines Agency Committee Issues Negative Opinion on Elevidys

MT Newswires Live
·
Jul 25

EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy

Reuters
·
Jul 25

Ema's Chmp: Recommended Not Granting a Marketing Authorisation for Elevidys for Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Jul 25

Sarepta Therapeutics Inc : RBC Cuts Target Price to $10 From $23

THOMSON REUTERS
·
Jul 25

Sarepta Therapeutics Shares Halted for Volatility, Last Down 14.4% at $11.40

THOMSON REUTERS
·
Jul 25